# A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

> **NCT01484587** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 24 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** CNTO 1959
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01484587
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-22
- **Primary completion:** 2013-04-11
- **Final completion:** 2013-04-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01484587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01484587, "A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01484587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*